Roche Pharmaceutical Development and Sales Overview
HER2+ franchise: Continued growth
Multiple Ph III combination trials initiated
Phesgo's strong global launch continues
50%
Global Phesgo conversion rate*
•
40%
30%
30%
20%
10%
0%
720
Q4 Q1 Q2
Q3 Q4 Q1 Q2 Q3
20 21 21 21 21 22 22 22
Phesgo conversion rate at 30% in early launch countries
Phesgo significantly cuts healthcare costs and resource use
P+H in eBC (APHINITY): 8-year follow up data presented at ESMO Virtual
Plenary showing a 28% reduction in the risk of recurrence or death for high
risk, lymph-node positive patients
•
⚫ Ph III (heredERA) Phesgo + giredestrant in 1L HER2+/HR+ mBC initiated
Kadcyla Roche
PHESGO®
ado-trastuzumab emtansine
for injection
Kadcyla growth driven by adjuvant setting
Neoadjuvant
50%
PHESGO®
HER2+
eBC pts
50%
Surgery
Adjuvant cont.
PCR (55%)
PHESGO®
Kadcyla
Residual
Disease (45%)
ado-trastuzumab emtansine
for injection
Adjuvant only
PHESGO®
• Continued growth enabled by global expansion in the adjuvant setting
•
•
Kadcyla remains SoC in adjuvant patients with residual disease
(KATHERINE) with > 60% of sales in the adjuvant setting
⚫ Ph III (KATE-3) Kadcyla + Tecentriq in 2L+ HER2+/PD-L1+ mBC initiated
⚫ Ph III (ASTEFANIA) Kadcyla + Tecentriq in HER2+/PD-L1+ eBC initiated
P=Perjeta; H-Herceptin; HR-Hormone receptor; HER2-Human epidermal growth factor receptor 2; BC-Breast cancer; eBC-Early breast cancer; mBC=Metastatic breast cancer; PCR-pathologic complete response;
SoC-standard of care; ESMO-European Society for Medical Oncology; *Phesgo conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (25 countries); Phesgo in
collaboration with Halozyme
20
20View entire presentation